Get started

Covid19stock

$MRNAModerna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, Metagenomi, Inc., and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd.; Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group; Aldevron, LLC; Institute for Life Changing Medicines; and AbCellera Biologics Inc. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
NASDAQ:MRNALong
by BADQOMOCAWGOWLD
Merck Stocks Have a 25% Growth PotentialToday we will review Merck & Co stocks as I have promised recently. The company announced the launch of the first oral medication against COVID-19 with proven efficiency. Let’s analyse the chart with the Merck stocks and their upside potential. When doing analysis it is traditionally better to start from the eldest timeframes to distinguish the existing trend. So, if we look at the monthly timeframe chart of Merck stocks we may find an upward trend that started in March 2009. We may also see a consolidation since January 2020 that lasted until September 2021, that is forming a triangle. This figure acts as a continuation sequence of the trend as the upward breakthrough has already been made. The breakthrough occurred on October 1, when the company announced successful clinical trial results of its anti-COVID-19 pill. This announcement was made a week before and no other news has been announced concerning this. This triangle provides a potential for Merck stocks to go to the $103.50-104 area. So, it is a potential gain of 25-26% from the current price. Moreover, the gap on October 1 is now acting as a key support level. Nevertheless, technically we may have a retest of the upper triangle margin at the $78.50-$79.30 area. But even if this retest does not happen, as it is not always the case, it is worth to consider adding these stocks to the portfolio. It should be noted that this technical pattern has been forming for several months and we should expect that the upside scenario would be effective for a while still. It may take 2-3 month, or even more, to reach the mentioned targets. However, such long-term technical patterns usually provide a good profit for those who are not looking for a checkered fortune.Merck has made contracts to deliver its pills not only in the United States, but also with other governments that are currently considering purchasing this new medication.
NYSE:MRKLong
by scavoanastasiia
AHT seems ready to rallyAs one of stocks that are significantly impacted by COVID, AHT price seems to be stable at current level (even if the market went down this month). Given that the last earning report looks good to me, I would open long as soon as this market correction ends. Besides the general trend analysis, there are some technical supports: resistance level 14.00 had been successfully tested 3 times. volume indicator BULL signal. Getting closer and closer to the 30 days moving average.
NYSE:AHTLong
by zozo9
$MRNA: a fine cup of coffee!After Pfiser's booster shot approval this month, $MRNA will surely follow. Today, they announced a combined flu and COVID shot, as well as signing a multi-year deal with a manufacturer, National Risilience Inc, which will help reach its 2021 goal of delivering 800M-1B doses of its vaccine. This has got the stock soaring and the rim of the cup is forming as you can see in my beautiful drawings. At least that's what my mom calls them. So, get ready for a pullback and then a trip to the moon! 😉🚀🚀🚀
NASDAQ:MRNALong
by alxiv
5
Aena S.M.E., S.A. (AENA.mc):We can found a technical figure Triangle in Spanish company Aena, SME S. A. (AENA.mc) on a daily chart. Aena, SME S. A.is a Spanish public company incorporated as a public limited company that manages general interest airports in Spain. The company, which is 51% owned by the public business entity ENAIRE, operates 45 airports and two heliports in Spain and participates through its subsidiary "Aena Internacional," in the management of 15 airports in Europe and America, which makes the company in the first airport operator in the world by a number of passengers. The Triangle has broken through the support line on 07/09/2021. If the price holds below this level, you can have a possible bearish price movement with a forecast for the next 12 days towards 130.70 EUR. According to the experts, your stop loss should be around 139.40 EUR if you enter this position. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
BME:AENAShort
by legacyFXofficial
COVID-19 - Evolutionary Curve ForecastIdea for COVID-19: - We believe that the fight against COVID-19 has entered the mid game. - Can COVID-19 be beaten in the game of evolution? We think so. Viruses are rational actors, and will behave as a population in the interests of their evolutionary fitness. - While the media's narrative of "wave 3" of COVID-19 has spread and is widely known, Motive Wave 2 of COVID-19 will begin in June 2021 (new wave 1 2 3), which will end at the end of 2022. Speculation: - Global vaccinations and pandemic responses have introduced strong selective pressure on the virus since the beginning of the year. - From summer to the end of the year, the virus will select a new dominant variant to dominate. Expectations for the end of Motive Wave 2 (2022-2023): - Uncontrolled Growth: 1.3 Billion+ infected, 21.8 Million+ deaths. - Infectivity and Vaccine resistance: 900 Million+ infected, 21.8 Million+ deaths. - Lethality: 470 Million+ infected, 16.4 Million+ deaths. - Severity/and or Vaccine resistance (without infectivity): 320 Million+ infected, 10.9 Million+ deaths. - Successful Vaccination: Infection should drop rapidly, but 5.4 Million+ deaths. To model total deaths , we fit the % curve of the moving average: Disclaimer: We absolutely do not provide financial advice in any shape or form. We do not recommend investing based on our opinions and strongly cautions that securities trading and investment involves high risk and that you can lose a lot of money. Loss of principal is possible. We do not recommend risking money you cannot afford to lose. We do not guarantee future performance nor accuracy in historical analyses. We are not registered investment advisors. Our ideas, opinions and statements are not a substitute for professional investment advice. We provide ideas containing impersonal market observations and our opinions. Our speculations may be used in preparation to form your own ideas.
C
by UnknownUnicorn1043646
4
Can Covid Vax Spark DVAX?DVAX retracement plotted using recent lows and the high from Aug 2018...figured that would be more than enough on the big picture to see any potential levels of interest. In this case, sure enough, there were. Mainly, the 236 fib line has been an area of higher traffic over the last 3 years. Further, DVAX has yet to establish a substantial support above this level for an extended period of time. Thanks to the Delta variant, COVID vax is in focus. For DVAX however, there are possibly a few other things to keep in mind that could be important to keep in mind right now: " Conveniently for those just beginning to look at DVAX stock right now, the company gave an overview of its platforms earlier this month in a second-quarter earnings update. Its HEPLISAV-B and CpG 1018 platforms generated revenue for the quarter, with $39 million coming from CpG 1018 and $13.7 million from HEPLISAV-B. In particular, the HEPLISAV-B revenues were the highest quarterly figures for the treatment to date. Dynavax has gone further and entered into a commercialization agreement with Bavarian Nordic for the German market...With the coronavirus continuing to stoke uncertainty, vaccine stocks remain in focus. Dynavax’s CpG 1018 adjuvant has acted as a recent catalyst. The adjuvant is designed to increase vaccine immune response when used in vaccines, including its own HEPLISAV-B. Now, with coronavirus vaccines showing benefits, the uptick in cases has helped build more interest in the company’s pipeline...In fact, Dynavax has entered into commercial supply agreements with numerous companies, including Biological E and Clover Biopharmaceuticals, to use Dynavax’s adjuvant in the commercial production of each company’s respective coronavirus vaccine candidates. " Quote Source + Read more: Hot Biotech Stocks That Deserve Your Attention In August 2021
NASDAQ:DVAX
by PennyStocks101
VXRT Vol + Fibs = ?VXRT testing another familiar area of "traffic" from the last few months. This 786 fib area has remained a key level on the chart. More times than not, VXRT has failed to break and hold above it for any meaningful amount of time. But thanks to new covid cases and its recent business update, things are popping on Aug 9th. Though the volume isn't anything crazy above average, the last few days of consistently higher levels are something to watch closely as well. " Another one of the former penny stocks to watch on this list is Vaxart Inc. While short interest isn’t the only focus right now, for VXRT, it has played a role. Based on the most recent data, the short float percentage is right around 20%. What’s more, the company’s recent business update helped shed a brighter light on a few things that were up in the air during more recent weeks...One of the topics discussed was the potential of Vaxart’s R&D and clinical development initiatives. CEO Andrei Floroiu said, “We strengthened our balance sheet, made major research advances, deepened our scientific knowledge, grew the company, and took the company closer to our goal of developing disruptive oral tablet vaccines that can have a material impact on the world’s public health.” ...Vaxart’s platform has shown progress in recent clinical trials. Its norovirus vaccine, built on the company’s VAAST platform, demonstrated the ability to boost immune responses in those who’ve been previously vaccinated with a Vaxart oral vaccine. In some cases, this vaccination period was more than a year earlier. The company also has a current trial study going on. This is of its S-Wuhan construct, which it expects to begin shortly. Obviously, with growing virus cases and the eventual rise of “cold and flu season,” this early progress has begun to gain attention in the market. " Quote Source & Read More: 4 Penny Stocks On Robinhood To Watch This Week
NASDAQ:VXRT
by PennyStocks101
Whatever WORX Right?WORX stock tested a key FIb level on Wednesday being the 50 fib line after plotting the top anchor at the recent high the first time WORX busted above the 50 fib. Before this latest round of testing, the last time WORX reached this key level it was rejected heavily. A few weeks ago, the company announced that it had regained compliance with the NASDAQ listing requirements. At the same time, it announced that Tim Hannibal, current COO, would become the new CEO. He stated that “over the last 10-15 years, technology within the healthcare industry has evolved both in cost and complexity. Unfortunately, the technology which was implemented within different hospital departments and with disparate objectives has failed to provide the promised advancements.” As a leader in providing software to healthcare institutions, there is a clear benefit that Scworx could gain from the pandemic’s current state and the ending of Covid-19. With all of this in mind, is WORX stock worth keeping an eye on? Quote source and read more: 4 Epicenter Penny Stocks You Need to Know About in 2021
NASDAQ:WORX
by PennyStocks101
Do you have Diamond Hands? Check out NXRP's Volatile Reversal...NRXP is in for a wild & volatile ride where it may reverse & double in value or even more. Technicals support a reversal over weeks with a current strong trend on the daily. Fundamentals are strong; F-Score is 9 & they just had some major news catalysts including a COVID-19 Treatment drug. High risk with potentially high reward: up to a 25% drawdown and a potential 100+% gain leading to a 4:1 risk to reward ratio. With a ~30% short interest this could be a wild ride like GME or AMC. Risk management by day trading may be possible.
NASDAQ:NRXPLong
by jsgiardino
Bullish ZoomAfter strong Q1 and Q2 earnings. With fears of delta covid variant. It seems that Zoom stock is about start a bull cycle. Beside the strong fundamentals and supportive circumstances. This convintion is also build upon chart technicals where the price has broke through a falling channel, and now testing the upper trend + 50 day moving average. As shown the candle stick is making a bullish hummer at the daily close which makes a positive Sign for a long entry. First target price is $440 and the second $500 with a chance for further upside. However, this play may takes sometime and hence patience is required.
NASDAQ:ZMLong
by MahdiAlQallaf
1
BIOV -- FDA approval for COVID-19 clinical trialsBiotech sector is getting hot, especially for companies connected to COVID-19 vaccine and treatments development... BIOV chart looks rip for a breakout with MACD closing in on bullish cross and a major catalyst in the form of FDA approval of its Phase I/II study: FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH VANCOUVER, British Columbia, July 22, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTCQB: BVAXF) ("BioVaxys"), is pleased to announce today that the US Food and Drug Administration ("FDA") has provided its official Written Response to the Company's request for a Pre-IND Type B review of CoviDTH as a diagnostic for evaluating T-cell immune response to SARS-CoV-2. The FDA found the Chemistry, Manufacturing and Controls, and other elements of the clinical development program proposed by BioVaxys to be acceptable and provided guidance and feedback supportive of BioVaxys' clinical development plans for CoviDTH. In addition, the FDA indicated that animal toxicity studies for CoviDTH were not required and that the Company could start its clinical development program with a combined Phase I/II study. Based on this feedback, BioVaxys will begin preparation of an IND application to support a Phase I/II safety, dosing, and efficacy study. BioVaxys submitted a Pre-Investigational New Drug ("IND") meeting request and briefing package with the FDA's Center for Biologics Evaluation and Research (CBER) for CoviDTH earlier this year. The Pre-IND review is a critical step in the US regulatory approval process, as it affords an opportunity for study sponsor companies to seek clarification from the FDA on clinical trials design, clinical materials manufacturing, quality controls, etc. "With the guidance we received from this FDA review, BioVaxys is now able to begin preparing its IND," stated BioVaxys President and Chief Operating Officer Ken Kovan. He adds "Although the FDA has indicated that our planned animal tox study is discretionary, we will likely continue with the animal tox study of CoviDTH as it does not interfere with the development time frame and may in fact provide useful data." James Passin, BioVaxys CEO, stated, "We are pleased to advance CoviDTH towards clinical trials, as we believe that mass screening for T cell immunity to Covid-19 will represent a critical tool for public health authorities to address the continued pandemic, as Covid variants continue to circulate and major governments in the southern hemisphere enact new lockdown policies." The Company is not making any express or implied claims that its product has the ability to eliminate, cure, or contain Covid-19 (SARS-CoV-2) at this time.
CSE:BIOVLong
by wealth_bakery
NVAX Novavax Analyst RatingsOn 6/15/2021 Cantor Fitzgerald brokerage Boosted the Price Target from Reduce to Overweight $217.00 to $272.00 On 5/18/2021 JPMorgan Chase & Co. brokerage Reiterated Rating from Overweight to Neutral $285.00 to $161.00 On 5/12/2021 B. Riley brokerage Lowered the Price Target from $365.00 to $286.00 On 5/12/2021 HC Wainwright brokerage Lowered the Price Target from $317.00 to $294.00 My personal price target is $240. Looking forward to read your opinion.
NASDAQ:NVAXLong
by TopgOptions
Biotech - CSLModel has given entry signals for CSL Limited: - CSL Limited is a global specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. - We are very excited about opportunities in the biotech sector, as we believe the fight against COVID is going to move to the next phase in the nearest future. - Technically in a Wyckoff accumulation structure with a spring, possibly testing the channel top. GLHF, DPT Disclaimer: We absolutely do not provide financial advice in any shape or form. We do not recommend investing based on our opinions and strongly cautions that securities trading and investment involves high risk and that you can lose a lot of money. Loss of principal is possible. We do not recommend risking money you cannot afford to lose. We do not guarantee future performance nor accuracy in historical analyses. We are not registered investment advisors. Our ideas, opinions and statements are not a substitute for professional investment advice. We provide ideas containing impersonal market observations and our opinions. Our speculations may be used in preparation to form your own ideas.
ASX:CSLLong
by UnknownUnicorn1043646
Vaccine Counter PHARMA Downtrend SignsSupposedly the beneficiary of the vaccine story as one of the appointees approved by the government. A duopoly with DPHARMA. However... their price & volume action is dimming fast.. The cup and handle pattern is invalidated. The recent decision to prioritize Pfizer vaccine over Sinovac really trigger a sell-down on PHARMA stock price with high volume. Expect continued selling in the coming days. www.straitstimes.com The rest of the vaccine related stock hype: Kanger, Solution, HWGB, Yongtai, Bintai , yet to see any new development as the government controlled tightly the distribution and sale of vaccine to the public from third parties. Disclaimer This information only serves as reference information and does not constitute a buy or sell call. Conduct your own research and assessment before deciding to buy or sell any stock
MYX:PHARMAShort
by Gilazilla
Is a perfect storm brewing?I am looking at potential short positions on OIL related stocks as indicated by this example. Observation Phillips 66 has gone into a bearish mode with swing traders (around 30% of the market) losing on net longs positions with the wider market on average now being at break even. Break-even price levels can mean either 1) important support areas, 2) break points where on-stop shorts can be positioned (without the risk of being affected by stop loss hunts) Discussion Several core issues to measure here: 1) OPEC - growing pump volumes' 2) USA dollar - and its purchasing power 3) US economy - is the US fiscal response still in-tact? 4) Covid-19 and economic recovery - new strains and 2nd / 3rd waves in countries - South Africa, USA etc. We could have a situation where OPEC volumes being increased intersect with economic wobbles and new Covid impacts. So a perfect storm may be brewing! Extra Two oscillators are presented: 1 - Realised PnL for this stock - If I saw large losses being realised and a new cost basis being set by the wider market , I would be more inclined to think that the current set-up is a pivot point low and potential buying opportunity - currently this is NOT the case! 2 - Exempt short volume - measures the 'Urgency' of shorts- or hedgers. These points come in just before or at Pivot Point highs or after Pivot Point lows for cover. So I will be keeping an eye on this. Good trading :)
NYSE:PSX
by Adam-Cox